Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma
Open Access
- 1 June 2008
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 10 (3) , 330-340
- https://doi.org/10.1215/15228517-2008-003
Abstract
We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases pKeywords
This publication has 36 references indexed in Scilit:
- Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)British Journal of Cancer, 2006
- Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08Clinical Cancer Research, 2006
- Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2005
- Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant gliomaCancer, 2005
- Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient seriesAnnals of Oncology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Platelet-Derived Growth Factor Production by B16 Melanoma Cells Leads to Increased Pericyte Abundance in Tumors and an Associated Increase in Tumor Growth RateCancer Research, 2004
- Imatinib sensitizes CLL lymphocytes to chlorambucilLeukemia, 2003
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNABiochemistry, 1994